Drugs / CD19-CD34t metabolically programmed CAR transduced T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05702853 | Nov 2023 → Nov 2026 expected | B-cell chronic lymphocytic leukemia | Medical University of South Carolina | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CD34t metabolically programmed CAR transduced T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05702853 ↗ |
| Modality | Cell therapy | “CD19- CD34t metabolically programmed CAR T-cell therapy” NCT05702853 ↗ |
| Route | Intravenous | “Cells are to be infused intravenously (IV)” NCT05702853 ↗ |
| Target | CD19 | “CD19 CAR T-cell therapy” NCT05702853 ↗ |